CANY
RCUS icon

Caxton Associates (New York)’s Arcus Biosciences RCUS Stock Holding History

Caxton Associates (New York)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,387
Closed -$461K – 670
2021
Q4 		$461K Buy
+11,387
New +$442K 0.05% 297

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Caxton Associates (New York)'s RCUS Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Arcus Biosciences (RCUS) in Q1 2022, closing a stake of 11,387 shares — an estimated $461K sold.

Caxton Associates (New York) first reported a position in RCUS in Q4 2021 and held it in 1 quarter. The position peaked at $461K in Q4 2021. 157 funds tracked by Wall St. Rank hold RCUS as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Arcus Biosciences position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,387 Arcus Biosciences shares in Q1 2022, an estimated $461K.
  • Caxton Associates (New York) first reported a position in Arcus Biosciences in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Arcus Biosciences position peaked at $461K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.